Read by QxMD icon Read

Sbrt lung cancer

Mazen Soufi, Hidetaka Arimura, Takahiro Nakamoto, Taka-Aki Hirose, Saiji Ohga, Yoshiyuki Umezu, Hiroshi Honda, Tomonari Sasaki
PURPOSE: We aimed to explore the temporal stability of radiomic features in the presence of tumor motion and the prognostic powers of temporally stable features. METHODS: We selected single fraction dynamic electronic portal imaging device (EPID) (n = 275 frames) and static digitally reconstructed radiographs (DRRs) of 11 lung cancer patients, who received stereotactic body radiation therapy (SBRT) under free breathing. Forty-seven statistical radiomic features, which consisted of 14 histogram-based features and 33 texture features derived from the graylevel co-occurrence and graylevel run-length matrices, were computed...
February 2018: Physica Medica: PM
Anastasia Oikonomou, Farzad Khalvati, Pascal N Tyrrell, Masoom A Haider, Usman Tarique, Laura Jimenez-Juan, Michael C Tjong, Ian Poon, Armin Eilaghi, Lisa Ehrlich, Patrick Cheung
We sought to quantify contribution of radiomics and SUVmax at PET/CT to predict clinical outcome in lung cancer patients treated with stereotactic body radiotherapy (SBRT). 150 patients with 172 lung cancers, who underwent SBRT were retrospectively included. Radiomics were applied on PET/CT. Principal components (PC) for 42 CT and PET-derived features were examined to determine which ones accounted for most of variability. Survival analysis quantified ability of radiomics and SUVmax to predict outcome. PCs including homogeneity, size, maximum intensity, mean and median gray level, standard deviation, entropy, kurtosis, skewness, morphology and asymmetry were included in prediction models for regional control (RC) [PC4-HR:0...
March 5, 2018: Scientific Reports
Cory Pierson, Taras Grinchak, Casey Sokolovic, Brandi Holland, Teresa Parent, Mark Bowling, Hyder Arastu, Paul Walker, Andrew Ju
BACKGROUND: The purpose of this study was to evaluate the prognostic impact of Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) and Response Evaluation Criteria in Solid Tumors (RECIST) and of pre- and post-treatment maximum Standard Uptake Value (SUVmax ) in regards to survival and tumor control for patients treated for early-stage non-small cell lung cancer (ES-NSCLC) with stereotactic body radiotherapy (SBRT). METHODS: This is a retrospective review of patients with ES-NSCLC treated at our institution using SBRT...
February 27, 2018: Radiation Oncology
Vanessa Figlia, Rosario Mazzola, Francesco Cuccia, Filippo Alongi, Gianluca Mortellaro, Daniela Cespuglio, Teresa Cucchiara, Giuseppina Iacoviello, Vito Valenti, Massimo Molino, Francesco Verderame, Domenica Matranga, Antonio Lo Casto, Giuseppe Ferrera
BACKGROUND: Several experiences in the literature report SBRT as an effective treatment option for medically inoperable early stage non-small cell lung cancer (NSCLC) and oligometastatic disease. The optimal fractionation schedules and total dose remain controversial. In this study, we evaluated the safety in terms of toxicity and efficacy of using of 8-10 fractions schedules with Helical Tomotherapy (HT) for primary and metastatic lung lesions. METHODS: Between March 2014 and May 2016, a total of 39 patients (median age 72 years, range 26-91) were treated with HT-SBRT for malignant lung lesions: 22 patients with early stage NSCLC, 17 with oligometastases...
February 17, 2018: La Radiologia Medica
Tingliang Zhuang, Neil M Woody, Han Liu, Sheen Cherian, Chandana A Reddy, Peng Qi, Anthony Magnelli, Toufik Djemil, Kevin L Stephans, Ping Xia, Gregory Mm Videtic
INTRODUCTION: Concerns were raised about the accuracy of pencil beam (PB) calculation and potential underdosing of medically inoperable non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT). From our institutional series, we designed a matched-pair study where each local failure and controlled patient was matched based upon several clinical factors, to investigate the dose difference between the matched-pair. METHODS: Eighteen pairs of NSCLC patients, treated with 50 Gy in five fractions, were selected...
February 5, 2018: Journal of Medical Imaging and Radiation Oncology
Henri B Wolff, Leonie Alberts, Elisabeth A Kastelijn, Birgit I Lissenberg-Witte, Jos W Twisk, Frank J Lagerwaard, Suresh Senan, Sherif Y El Sharouni, Franz M N H Schramel, Veerle M H Coupé
INTRODUCTION: There is an ongoing debate on the optimal treatment for stage I non-small cell lung cancer (NSCLC), with increasing evidence for comparable health outcomes after surgery or stereotactic body radiation therapy (SBRT). For clinical decision making, the experienced quality of life, summarized as health utility, is of importance to choose between treatments. In this study, we evaluated differences in longitudinal health utility in stage I NSCLC in the first year after surgical resection versus SBRT, before any recurrence of disease...
January 29, 2018: Journal of Thoracic Oncology
Mitsuhiro Nakamura, Yoshitomo Ishihara, Yukinori Matsuo, Yusuke Iizuka, Nami Ueki, Hiraku Iramina, Hideaki Hirashima, Takashi Mizowaki
Knowledge of the imaging doses delivered to patients and accurate dosimetry of the radiation to organs from various imaging procedures is becoming increasingly important for clinicians. The purposes of this study were to calculate imaging doses delivered to the organs of lung cancer patients during real-time tumor tracking (RTTT) with three-dimensional (3D), and four-dimensional (4D) cone-beam computed tomography (CBCT), using Monte Carlo techniques to simulate kV X-ray dose distributions delivered using the Vero4DRT...
January 27, 2018: Journal of Radiation Research
Kazuki Kubo, Hajime Monzen, Mikoto Tamura, Makoto Hirata, Kentaro Ishii, Wataru Okada, Ryuta Nakahara, Shun Kishimoto, Ryu Kawamorita, Yasumasa Nishimura
It is important to improve the magnitude of dose variation that is caused by the interplay effect. The aim of this study was to investigate the impact of the number of breaths (NBs) to the dose variation for VMAT-SBRT to lung cancer. Data on respiratory motion and multileaf collimator (MLC) sequence were collected from the cases of 30 patients who underwent radiotherapy with VMAT-SBRT for lung cancer. The NBs in the total irradiation time with VMAT and the maximum craniocaudal amplitude of the target were calculated...
January 25, 2018: Journal of Applied Clinical Medical Physics
Kevin L Stephans, Neil M Woody, Chandana A Reddy, Matthew Varley, Anthony Magnelli, Tingliang Zhuang, Peng Qi, Gregory M M Videtic
PURPOSE: To examine the impact of stereotactic body radiation therapy (SBRT) dose on outcomes in early-stage non-small cell lung cancer in a large single-institution series. METHODS AND MATERIALS: We reviewed 600 patients treated from 2003 to 2012 for early-stage non-small cell lung cancer. The SBRT dose was at physician discretion on the basis of tumor size and location. Peripheral tumors were treated to 60 Gy in 3 fractions (homogeneous planning), 48-50 Gy in 4-5 fractions, or 30-34 Gy in 1 fraction...
February 1, 2018: International Journal of Radiation Oncology, Biology, Physics
William A Stokes, Michael R Bronsert, Robert A Meguid, Matthew G Blum, Bernard L Jones, Matthew Koshy, David J Sher, Alexander V Louie, David A Palma, Suresh Senan, Laurie E Gaspar, Brian D Kavanagh, Chad G Rusthoven
Purpose In early-stage non-small cell lung cancer (NSCLC), post-treatment mortality may influence the comparative effectiveness of surgery and stereotactic body radiotherapy (SBRT), with implications for shared decision making among high-risk surgical candidates. We analyzed early mortality after these interventions using the National Cancer Database. Patients and Methods We abstracted patients with cT1-T2a, N0, M0 NSCLC diagnosed between 2004 and 2013 undergoing either surgery or SBRT. Thirty-day and 90-day post-treatment mortality rates were calculated and compared using Cox regression and propensity score-matched analyses...
January 18, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
S Mokhles, J J M E Nuyttens, M de Mol, J G J V Aerts, A P W M Maat, Ö Birim, A J J C Bogers, J J M Takkenberg
BACKGROUND: The objective of this study is to investigate the role and experience of early stage non-small cell lung cancer (NSCLC) patient in decision making process concerning treatment selection in the current clinical practice. METHODS: Stage I-II NSCLC patients (surgery 55 patients, SBRT 29 patients, median age 68) were included in this prospective study and completed a questionnaire that explored: (1) perceived patient knowledge of the advantages and disadvantages of the treatment options, (2) experience with current clinical decision making, and (3) the information that the patient reported to have received from their treating physician...
January 15, 2018: BMC Cancer
Ronghu Mao, Lingling Tian, You Zhang, Lei Ren, Renqi Gao, Fang-Fang Yin, Hong Ge
OBJECTIVE: The objective of this study is to theoretically and experimentally evaluate the dosimetry in the microscopic disease regions surrounding the tumor under stereotactic body radiation therapy of lung cancer. METHODS: For simplicity, the tumor was considered moving along 1 dimension with a periodic function. The probability distribution function of the tumor position was generated according to the motion pattern and was used to estimate the delivered dose in the microscopic disease region...
December 2017: Technology in Cancer Research & Treatment
Marianne Camille Aznar, Samantha Warren, Mischa Hoogeman, Mirjana Josipovic
Stereotactic body radiotherapy (SBRT) for lung tumours has been gaining wide acceptance in lung cancer. Here, we review the technological evolution of SBRT delivery in lung cancer, from the first treatments using the stereotactic body frame in the 1990's to modern developments in image guidance and motion management. Finally, we discuss the impact of current technological approaches on the requirements for quality assurance as well as future technological developments.
January 10, 2018: Physica Medica: PM
L Ye, F Xu, S Shi, Z Zeng, X Jin, Y Huang, C Lu, J Gu, D Ge, J He
BACKGROUND: The value of maximum standard uptake value (SUVmax ) was overlooked in current studies comparing stereotactic body radiotherapy (SBRT) versus surgery for stage I non-small cell lung cancer (NSCLC). Herein, we aimed to compare the 3-year outcomes based on patients for whom SUVmax were available, and to explore the role of SUVmax in clinical decision-making. METHODS: From January 2010 to June 2016, data of eligible patients were collected. Patient variables and clinical outcomes were compared in both unmatched and matched groups using propensity score matching (PSM)...
January 11, 2018: Clinical & Translational Oncology
Pietro Mancosu, Andrew Nisbet, Núria Jornet
Stereotactic body radiation therapy (SBRT) has become a standard treatment for non-operable patients with early stage non-small cell lung cancer (NSCLC). In this context, medical physics community has largely helped in the starting and the growth of this technique. In fact, SBRT requires the convergence of many different features for delivering large doses in few fractions to small moving target in an heterogeneous medium. The special issue of last month, was focused on the different physics challenges in lung SBRT...
January 9, 2018: Physica Medica: PM
Carole Dennie, Rebecca Thornhill, Carolina A Souza, Cecilia Odonkor, Jason R Pantarotto, Robert MacRae, Graham Cook
Background: The prediction of local recurrence (LR) of stage I non-small cell lung cancer (NSCLC) after definitive stereotactic body radiotherapy (SBRT) remains elusive. The purpose of this study was to assess whether quantitative imaging features on pre-treatment computed tomography (CT) can predict LR beyond 18 (18F) fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT maximum standard uptake value (SUVmax). Methods: This retrospective study evaluated 36 patients with 37 stage I NSCLC who had local tumor control (LC; n=19) and (LR; n=18)...
December 2017: Quantitative Imaging in Medicine and Surgery
Michela Roberto, Rosa Falcone, Federica Mazzuca, Livia Archibugi, Nadia Castaldi, Andrea Botticelli, Mattia Falchetto Osti, Paolo Marchetti
RATIONALE: Regorafenib is the new standard third-line therapy in metastatic colorectal cancer (mCRC). However, the reported 1-year overall survival rate does not exceed 25%. PATIENT CONCERNS: A 55-year-old man affected by mCRC, treated with regorafenib combined with stereotactic body radiotherapy (SBRT), showing a durable response. INTERVENTIONS: After 6 months of regorafenib, a PET/CT scan revealed a focal uptake in a solid lung nodule which was treated with SBRT, whereas continuing regorafenib administration...
December 2017: Medicine (Baltimore)
Rezarta Frakulli, Fabrizio Salvi, Damiano Balestrini, Marcella Palombarini, Ilir Akshija, Silvia Cammelli, Alessio Giuseppe Morganti, Maurizio Zompatori, Giovanni Frezza
Background: Parenchymal changes after stereotactic body radiation therapy (SBRT) make differential diagnosis between treatment outcomes and disease recurrence often difficult. The purpose of our study was to identify the radiographic features detectable at computed tomography (CT) scan [high-risk features (HRFs)] that allow enough specificity and sensitivity for early detection of recurrence. Methods: We retrospectively evaluated patients who underwent SBRT for inoperable early stage non-small cell lung cancer (NSCLC)...
December 2017: Translational Lung Cancer Research
Hui Luo, Hong Ge, Yingying Cui, Jiangong Zhang, Ruitai Fan, Anping Zheng, Xiaoli Zheng, Yanan Sun
Background: Increasing evidence indicates a relationship between systemic inflammation and survival following treatment in various tumors. However, the correlation of systematic inflammation with survival after stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer (NSCLC) has not been well established. Patients and methods: We retrospectively analyzed patients with newly diagnosed early stage NSCLC treated with SABR in a single institution from 2011 to 2015. The neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and lymphocyte- monocyte ratio (LMR) were calculated as systemic inflammation biomarkers...
2018: Journal of Cancer
Zachary D Horne, Adam H Richman, Michael J Dohopolski, David A Clump, Steven A Burton, Dwight E Heron
OBJECTIVES: The seminal phase II trial for pulmonary stereotactic body radiation therapy (SBRT) suggested that SBRT to central lesions resulted in unacceptable toxicity. Alternative dose-fractionation schemes have been proposed which may improve safety without compromise of efficacy. We report our institutional outcomes of SBRT for hilar/mediastinal non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: A retrospective review was conducted of patients with NSCLC in a hilar or mediastinal nodal station which was treated with SBRT...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"